Support and Resistance Levels
Past performance
About ERIS Lifesciences Ltd Eris Lifesciences Limited, founded in 2007, is a prominent player in India's pharmaceutical landscape, focusing on the development, manufacturing, and commercialization of branded pharmaceutical products. The company specializes in chronic and acute therapeutic areas, including cardiovascular, anti-diabetic, gastroenterology, and anti-infective segments, with a strong emphasis on lifestyle-related disorders. Eris operates a manufacturing plant in Guwahati, Assam, and maintains an extensive distribution network comprising 22 sales depots, 2,059 stockists, and over 500,000 retail chemists.
Since its public debut in 2017, Eris has expanded its portfolio through strategic acquisitions, including UTH Healthcare and the Indian branded formulations business of Strides Shasun. It has launched various divisions targeting specific therapeutic areas, such as cardiology, gastroenterology, gynecology, and orthopedics. Recent expansions include the acquisition of dermatology brands from Glenmark and cosmetology brands from Dr. Reddy's, alongside the launch of new products like Glura and human insulin. The company operates with five subsidiaries, focusing on growing its presence in the healthcare sector.